Edgar Filing: Patterson Matthew R - Form 4

Patterson Ma	atthew R										
Form 4	4 2009										
December 04										PROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMMISSION	OMB OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. SECURITIES SECURITIES Section 16. SECURITIES											
(Print or Type I	Responses)										
Patterson Matthew R Symbol				er Name and Ticker or Trading US THERAPEUTICS INC D]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
			e of Earliest Transaction h/Day/Year) 2/2008			Director 10% Owner Officer (give title Other (specify below) Chief Operating Officer					
			mendment, Date Original Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
CRANBUR	Y, NJ 08512							Person		porting	
(City)	(State)	(Zip)	Tab	le I - Non-E	Derivative S	Securi	ties Acqu	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Da (Month/Day/Year	r) Execution any		3. Transactic Code (Instr. 8) Code V	4. Securit or(A) or Dis (Instr. 3, 4) Amount	posed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	12/02/2008			М	20,098	A	\$ 0.638	56,547	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Patterson Matthew R - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day	Date	7. Title and J Underlying S (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 0.638	12/02/2008		М	20,098	<u>(1)</u>	12/15/2014	Common Stock	20,098

Reporting Owners

Reporting Owner Name / Address	Relationships					
F	Director	10% Owner	Officer	Other		
Patterson Matthew R C/O AMICUS THERAPEUTICS, INC. 6 CEDAR BROOK DRIVE CRANBURY, NJ 08512			Chief Operating Officer			
Signatures						

/s/ Matthew R.	12/04/2008
Patterson	12/04/2008

**Signature of Reporting Date Person

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These options vested and became exercisable in a series of installments. The first installment, which consisted of 25% of the total

aggregate number of options granted, vested on December 1, 2005 and the remaining options vested and became exercisable in a series of thirty-five successive equal monthly installments of 2,012 shares, beginning on January 1, 2006, with the final installment of 1,990 shares becoming exercisable on December 1, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.